Stockreport

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

LENZ Therapeutics, Inc.  (LENZ) 
PDF – LNZ100 selected as lead candidate– Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours– Rapid o [Read more]